Peeved Bayer to USTR: Indian govt picking winners

The Indian Nexavar (sorafenib tosylate) compulsory licensing case is still pressing on a raw nerve with Bayer and the German multinational is clearly very peeved with India's handling of intellectual property rights (IPR)-related issues.